The announcement is actually a reminder about how far Clarity is from revenue, which in turn highlights its capital inadequacy and the reason why its been sold off and shorted.
SABRE last patient in was November 2023, so its taken 19 months just to report topline results of a small diagnostic trial.
When Clarity did its $2.55 capital raise in March 2024, many people - including participating brokers and institutions - were forecasting first revenues by late 2025 or early 2026 - so 18-ish months after the capital raise. 15 months on, and (at least from the perspective of commercialising a product), revenue looks to be at least two years away - remembering that even for Phase 2 diagnostic trials, results aren't available until 12-18 months after the last patient in. So complete a Phase 3, analyse results, apply for registration and then start marketing - sounds like 2 years from now, minimum.
Could Alan deliver some sort of licensing deal earlier than that as a way to reduce equity raises? Possibly. But CU6 has been trading at "chicken-feed-for-a-BP" for a long time now, and there's been no discernible interest. In fact, shorters have only been emboldened and one would think that if there was a sniff of a licensing deal, they'd be the first to know.
Positive trial results will be of value if / when Clarity gets to commercialise something, but until then, they are often a reminder of how far away commercialisation is.
CU6 Price at posting:
$2.15 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)